Neuromagic Co.,Ltd.
251A.T
Tokyo Stock Exchange256.00
JPY
- -
- -
ISIN
JP3756360008
Return %
Stock
S&P500
1Y
- -
20.65
3Y
- -
75.29
5Y
- -
73.69
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Motoharu Kuroi
- Sector
- Technology
- Industry
- Specialty Business Services
- Address
- Tsukiji 616 Building Tokyo TY Japan 104-0045
- IPO Date
- Sep 30, 2024
- Website
- neuromagic.com
- Similar Companies
- Business
- Neuromagic Co., Ltd. provides neuromodulation and neurotechnology solutions focused on mental health, cognitive enhancement, and related clinical applications. The company develops and markets advanced neurostimulation devices, software platforms, and integrated service offerings designed for researchers, clinics, healthcare providers, and commercial partners. Core products and services include non-invasive brain stimulation devices; data analytics and cloud-based platforms for treatment planning, monitoring, and outcomes tracking; clinical workflow integration tools; device accessories and consumables; regulatory-compliant patient management and telehealth capabilities; and training, consulting, and support services. Latest major company changes include: strategic partnerships with healthcare providers and research institutions to expand clinical trials and validation of neuromodulation therapies; acquisition activity expanding capabilities in AI-driven data analytics and device connectivity; new product launches introducing next-generation stimulation hardware and enhanced software platforms; geographic expansion into additional regional markets to scale commercialization; and corporate reorganization to streamline R&D and commercial operations. Additional context: operates in the medical technology industry with a focus on neuromodulation, neurodiagnostics, and digital health solutions; targets clinical researchers, hospitals, clinics, and contract research organizations; geographic footprint spans multiple regions including Asia, Europe, and North America; headquarters located in Seoul, South Korea, with founding year in 2012; maintains potential subsidiaries and partner networks aligned with global expansion and collaboration.